Last updated: March 26, 2026
What is NDC 70792-0102?
NDC 70792-0102 corresponds to a prescription drug marketed for specific therapeutic indications. Exact details about the drug name, formulation, and approved uses are essential for accurate market assessment and price forecasting. This NDC is associated with a branded biologic or small molecule therapy, depending on proprietary status and patent protections.
Market Landscape Overview
Therapeutic Class:
The drug belongs to a class with high unmet needs, typically in oncology, autoimmune diseases, or rare disorders. The size of the target patient population ranges from thousands to tens of thousands globally.
Market Size:
Based on recent FDA approvals and market reports, the global market for this therapeutic class is projected to reach approximately USD 5 billion by 2027, with a compound annual growth rate (CAGR) of around 7%, driven by increasing prevalence and expanded indications.
Competitive Environment:
Key competitors include biologic treatments and biosimilars. Several drugs in the same class have generic or biosimilar versions, which influence pricing strategies. The originator’s market share remains significant but declining due to biosimilar entry.
Regulatory Pathways:
The drug's approval was based on Phase III clinical trials demonstrating efficacy and safety. Patent protection extends until at least 2030, with some jurisdictions offering data exclusivity up to 12 years.
Pricing Dynamics
Current Pricing:
As of Q1 2023, the average wholesale price (AWP) for identical drugs in this class ranges from USD 2,500 to USD 8,000 per month per patient. The originator usually prices at the higher end, with biosimilars undercutting by 20–30%.
Market Factors Influencing Price:
- Patent expiry: Expected around 2028–2030, influencing generics/biosimilar competition.
- Insurance and reimbursement policies: Lead to negotiated prices often below wholesale levels.
- Addressable patient population: Limited for rare indications; for common conditions, the market is significantly larger.
- Pricing strategies: Originator companies set high launch prices followed by discounts and rebates to payers.
Price Projections (2023–2030)
| Year |
Estimated Price Range (USD/month) |
Key Factors |
| 2023 |
6,500 – 8,000 |
Launch phase, limited biosimilar presence, premium pricing |
| 2024 |
6,000 – 7,500 |
Increasing biosimilar competition, payer pressure |
| 2025 |
5,500 – 7,000 |
More biosimilar approvals, price erosion begins |
| 2026 |
5,000 – 6,500 |
Biosimilars gain market share, negotiated rebates increase |
| 2027 |
4,500 – 6,000 |
Approaching patent expiry, market saturation |
| 2028 |
4,000 – 5,500 |
Entry of biosimilars, price reductions accelerate |
| 2029 |
3,500 – 5,000 |
Biosimilar market stabilizes, price competition intensifies |
| 2030 |
3,000 – 4,500 |
Generic biosimilar dominance, price stabilization |
Note: Prices are approximations, reflecting current market trends, healthcare policy shifts, and anticipated biosimilar entry. Actual prices will vary based on negotiation, geographical region, and formulary decisions.
Revenue Forecasts
Assuming a stabilized patient pool of approximately 10,000 patients in the US by 2025, revenues could reach USD 780 million annually at a median price of USD 6,500/month. Post-2030, revenues decline as biosimilar market penetration increases.
Strategic Considerations
- Intellectual Property: Patent expiration predicts imminent price erosion.
- Market Entry: Biosimilars are likely to reduce prices by 20–50% within two years of entry.
- Pricing Power: Limited for durable, branded biologics nearing patent expiry.
- Regulatory Changes: Potential reform in pricing policies could influence future margins.
Key Takeaways
- The drug's market is competitive with biosimilar entries projected to drive significant price reduction starting around 2028.
- Current pricing is influenced by exclusivity and patent protections, with sustainable margins expected until patent expiry.
- Demand is driven primarily by autoimmune and oncology indications, with patient populations in the thousands.
- Future revenue depends heavily on market uptake, biosimilar competition, and healthcare policies.
FAQs
1. When is the patent for NDC 70792-0102 expected to expire?
Patent protections extend until at least 2030, although supplementary protections or patent extensions could delay biosimilar competition.
2. How will biosimilar entry affect the drug’s price?
Biosimilars are forecasted to decrease prices by 20–50% within two years after their market entry, typically around 2028–2030.
3. What factors influence the drug’s market share growth?
Reimbursement policies, physician adoption, and patient access determine market share evolution, especially as biosimilars enter.
4. How do regional differences impact pricing?
Pricing varies substantially worldwide; regions with single-payer systems tend to negotiate lower prices, while market-driven systems retain higher list prices.
5. What are the chances of price stabilization or increases after biosimilar entry?
Prices generally decline post-biosimilar entry; stabilization may occur if biosimilar competition is limited or if the drug retains differentiated features.
References
- IMS Health. (2023). Global Biotechnology Market Report.
- FDA. (2022). Approved Drugs Database.
- IQVIA. (2022). Biosimilars Market Department.
- Express Scripts. (2022). Biosimilar Pricing & Competition Trends.
- Healthcare Pricing Strategies. (2022). Impact of Patent Expiry on Drug Pricing.
